‘Non-Drowsy’ Robitussin Makers Agrees to $4.5 Million Settlement

July 23, 2024, 10:23 PM UTC

The maker of over-the-counter cough and flu medicine Robitussin agreed to a non-reversionary $4.5 million settlement resolving claims it deceptively advertised products containing dextromethorphan as “non-drowsy.”

The settlement will go to consumers who purchased Robitussin products with the non-drowsy label between February 2016 and the date the court preliminarily approves the proposed settlement, the approval motion filed Monday in the US District Court for the Southern District of New York said.

  • Consumers alleged the non-drowsy statement was misleading because DXM can cause sleepiness
  • The suit was dismissed in 2023 because their claims were preempted by federal over-the-counter drug regulations, but ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.